Join to View Full Profile
920 US-202 SRaritan, NJ 08869
Phone+1 908-927-3159
Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
Rhode Island Hospital/Brown University HealthInternship, Internal Medicine, 2004 - 2005
The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
NY State Medical License 2006 - 2027
Clinical Trials
Publications & Presentations
PubMed
- CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.Simon J Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li, Tamia Nguyen
The New England Journal of Medicine. 2025-02-13 - Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database.Binod Dhakal, Jinghua He, Jordan M Schecter, William Deraedt, Ana Slaughter
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-23 - 1 citationsCharacteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level da...Kwee Yong, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt
European Journal of Cancer. 2025-01-17
Abstracts/Posters
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021
Press Mentions
JnJ Gets European Commission Nod for Subcutaneous Darzalex-Based Quadruplet Regimen for Newly Diagnosed Multiple MyelomaApril 10th, 2025- DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj) Shows 51 Percent Reduction in Risk of Progression to Active Multiple Myeloma for Patients with High-Risk Smoldering Multiple MyelomaDecember 8th, 2024
- Carvykti Lowering Risk of Death as Second-Line Myeloma Therapy: TrialOctober 1st, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
